The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Tumor necrosis factor signaling
Wajant, H., Pfizenmaier, K., & Scheurich, P. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401189 · Cited by 2,359
Flynn, J. L., Goldstein, M. M., Chan, J., Triebold, K. J., Pfeffer, K., Lowenstein, C. J., Schrelber, R., Mak, T. W., & Bloom, B. R. (1995) · Immunity · doi:10.1016/1074-7613(95)90001-2 · Cited by 1,677
Kindler, V., Sappino, A.-P., Grau, G. E., Piguet, P.-F., & Vassalli, P. (1989) · Cell · doi:10.1016/0092-8674(89)90676-4 · Cited by 1,254
Rothe, J., Lesslauer, W., Lötscher, H., Lang, Y., Koebel, P., Köntgen, F., Althage, A., Zinkernagel, R., Steinmetz, M., & Bluethmann, H. (1993) · Nature · doi:10.1038/364798a0 · Cited by 1,245
Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E., & Beenhouwer, D. O. (2004) · Clinical Infectious Diseases · doi:10.1086/383317 · Cited by 977
Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review
Pai, M., Riley, L. W., & Colford, J. M. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)01206-x · Cited by 913
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & Zinsmeister, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 910
Roach, D. R., Bean, A. G. D., Demangel, C., France, M. P., Briscoe, H., & Britton, W. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4620 · Cited by 782
Gardam, M. A., Keystone, E. C., Menzies, R., Manners, S., Skamene, E., Long, R., & Vinh, D. C. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00545-0 · Cited by 752
Van den Brande, J. M. H., Braat, H., van den Brink, G. R., Versteeg, H. H., Bauer, C. A., Hoedemaeker, I., van Montfrans, C., Hommes, D. W., Peppelenbosch, M. P., & van Deventer, S. J. H. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00382-2 · Cited by 723
(2005) · PsycEXTRA Dataset · doi:10.1037/e548692006-002 · Cited by 691
Infections in patients with rheumatoid arthritis treated with biologic agents
Listing, J., Strangfeld, A., Kary, S., Rau, R., von Hinueber, U., Stoyanova‐Scholz, M., Gromnica‐Ihle, E., Antoni, C., Herzer, P., Kekow, J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21386 · Cited by 681
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists
Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X.-Y., Shealy, D., & Wagner, C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.418 · Cited by 672
Carmona, L., Gómez‐Reino, J. J., Rodríguez‐Valverde, V., Montero, D., Pascual‐Gómez, E., Mola, E. M., Carreño, L., Figueroa, M., & BIOBADASER Group (2005) · Arthritis & Rheumatism · doi:10.1002/art.21043 · Cited by 656
Lügering, A., Schmidt, M., Lügering, N., Pauels, H.-G., Domschke, W., & Kucharzik, T. (2001) · Gastroenterology · doi:10.1053/gast.2001.28702 · Cited by 588
Masur, P. B. H., Kaplan, J. E., & Holmes, K. K. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_2-200209031-00002 · Cited by 567
Mohan, V. P., Scanga, C. A., Yu, K., Scott, H. M., Tanaka, K. E., Tsang, E., Tsai, M. C., Flynn, J. L., & Chan, J. (2001) · Infection and Immunity · doi:10.1128/iai.69.3.1847-1855.2001 · Cited by 536
Global Incidence of Multidrug‐Resistant Tuberculosis
Zignol, M., Hosseini, M. S., Wright, A., Weezenbeek, C. L., Nunn, P., Watt, C. J., Williams, B. G., & Dye, C. (2006) · The Journal of Infectious Diseases · doi:10.1086/505877 · Cited by 524
Extrapulmonary Tuberculosis in the United States
Rieder, H. L., Snider, D. E., & Cauthen, G. M. (1990) · American Review of Respiratory Disease · doi:10.1164/ajrccm/141.2.347 · Cited by 466
Baert, F. J., D'Haens, G. R., Peeters, M., Hiele, M. I., Schaible, T. F., Shealy, D., Geboes, K., & Rutgeerts, P. J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70224-6 · Cited by 462
British Thoracic Society Standards of Care Committee (2005) · Thorax · doi:10.1136/thx.2005.046797 · Cited by 432
Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy
Wolfe, F., Michaud, K., Anderson, J., & Urbansky, K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20009 · Cited by 431
Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection
Tufariello, J. M., Chan, J., & Flynn, J. L. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00741-2 · Cited by 403
Tumor necrosis factor: Biology and therapeutic inhibitors
Papadakis, K. A., & Targan, S. R. (2000) · Gastroenterology · doi:10.1053/gast.2000.18160 · Cited by 357
Treatment of Sarcoidosis With Infliximab
Doty, J. D., Mazur, J. E., & Judson, M. A. (2005) · Chest · doi:10.1378/chest.127.3.1064 · Cited by 312
Tuberculosis following the Use of Etanercept, a Tumor Necrosis Factor Inhibitor
Mohan, A. K., Timothy, R. C., Block, J. A., Manadan, A. M., Siegel, J. N., & Braun, M. M. (2004) · Clinical Infectious Diseases · doi:10.1086/421494 · Cited by 303
Infections and anti–tumor necrosis factor α therapy
Ellerin, T., Rubin, R. H., & Weinblatt, M. E. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11301 · Cited by 284
Scott Algood, H. M., Lin, P. L., & Flynn, J. L. (2005) · Clinical Infectious Diseases · doi:10.1086/429994 · Cited by 278
Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists
Bergstrom, L., Yocum, D. E., Ampel, N. M., Villanueva, I., Lisse, J., Gluck, O., Tesser, J., Posever, J., Miller, M., Araujo, J., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20454 · Cited by 268
Catrina, A. I., Trollmo, C., af Klint, E., Engstrom, M., Lampa, J., Hermansson, Y., Klareskog, L., & Ulfgren, A. K. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20764 · Cited by 255
Infections Associated With Tumor Necrosis Factor-α Antagonists
Crum, N. F., Lederman, E. R., & Wallace, M. R. (2005) · Medicine · doi:10.1097/01.md.0000180044.19285.9a · Cited by 225
Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Burmester, G. R., Bijlsma, J. W. J., Dougados, M., Emery, P., Keystone, E. C., Klareskog, L., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044941 · Cited by 225
Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept
Shen, C., Assche, G. V., Colpaert, S., Maerten, P., Geboes, K., Rutgeerts, P., & Ceuppens, J. L. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02309.x · Cited by 223
Granulomatous Infections Due to Tumor Necrosis Factor Blockade: Correction
Wallis, R. S., Broder, M., Wong, J., & Beenhouwer, D. (2004) · Clinical Infectious Diseases · doi:10.1086/424455 · Cited by 219
Reactivation of Latent Granulomatous Infections by Infliximab
Wallis, R. S., Broder, M., Wong, J., Lee, A., & Hoq, L. (2005) · Clinical Infectious Diseases · doi:10.1086/429996 · Cited by 191
Bekker, L.-G., Freeman, S., Murray, P. J., Ryffel, B., & Kaplan, G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6728 · Cited by 166
Jüttner, S., Bernhagen, J., Metz, C. N., Röllinghoff, M., Bucala, R., & Gessner, A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.5.2383 · Cited by 153
Tissot, F., Zanetti, G. M. R., Francioli, P. B., Jp, Z., & Zysset, F. (2004) · Clinical Infectious Diseases · doi:10.1086/426434 · Cited by 151
Jüttner, S., Bernhagen, J., Metz, C. N., Röllinghoff, M., Bucala, R., & Gessner, A. (1998) · PubMed · Cited by 147
O’Brien, D. P., Briles, D. E., Szalai, A. J., Tu, A.-H. T., Sanz, I., & Nahm, M. H. (1999) · Infection and Immunity · doi:10.1128/iai.67.2.595-601.1999 · Cited by 93
Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection.
Long, R., & Gardam, M. A. (2003) · PubMed · Cited by 88
Advances in the therapy of Wegener's granulomatosis
Hellmich, B., Lamprecht, P., & Gross, W. L. (2005) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000200369.24793.f5 · Cited by 60
Agnholt, J. S., Dahlerup, J. F., & Kaltoft, K. (2003) · Cytokine · doi:10.1016/s1043-4666(03)00201-1 · Cited by 60
"Compendium of pharmaceuticals and specialties".
Geekie, D. A. (1977) · PubMed · Cited by 47
Moore, T. A., Lau, H. Y., Cogen, A. L., & Standiford, T. J. (2005) · Clinical Infectious Diseases · doi:10.1086/430126 · Cited by 36
Cited by
Why have clinical trials in sepsis failed?
Marshall, J. C. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.01.007 · Cited by 805
Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle
Ishikawa, E., Ishikawa, T., Morita, Y. S., Toyonaga, K., Yamada, H., Takeuchi, O., Kinoshita, T., Akira, S., Yoshikai, Y., & Yamasaki, S. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20091750 · Cited by 792
Narasimhan, P., Wood, J., MacIntyre, C. R., & Mathai, D. (2013) · Pulmonary Medicine · doi:10.1155/2013/828939 · Cited by 731
Nontuberculous Mycobacteria Infections and Anti–Tumor Necrosis Factor-α Therapy
Winthrop, K. L., Chang, E., Yamashita, S., Iademarco, M. F., & LoBue, P. A. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1510.090310 · Cited by 320
Self-citationEarly Diagnosis and Treatment of Rheumatoid Arthritis
Littlejohn, E. A., & Monrad, S. U. (2018) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2018.02.010 · Cited by 315
Metadata
- Authors
- Winthrop, K. L.
- Venue
- Nature Clinical Practice Rheumatology
- Published
- 2006-11
- Volume
- 2
- Issue
- 11
- Pages
- 602-610
- ISSN
- 1745-8382 (ISSN-L)
- 1745-8390
- OpenAlex
- W2058050795
- Cited by
- 280
- References
- 46
- FWCI
- 18.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.